Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U6KH
|
|||
| Former ID |
DCL000527
|
|||
| Drug Name |
Figitumumab
|
|||
| Synonyms |
AC1OCENC; (2R)-3-[(4S,6R,7R,10S)-4-[(E,2R)-4-[(2S,2'S,4R,4aS,6R,8aR)-4-hydroxy-2-[(1S,3S)-1-hydroxy-3-[(6S,9R,10S)-9-methyl-5,11-dioxaspiro[5.5]undecan-10-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-7-hydroxy-2-methyl-5,11-dioxaspiro[5.5]undec-1-en-10-yl]-2-hydroxy-2-methylpropanoic acid
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Malignant adrenal gland cancer [ICD-11: 2D11] | Discontinued in Phase 1 | [1] | |
| Company |
Pfizer
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020634) | |||
| REF 2 | Pfizer. Product Development Pipeline. March 31 2009. | |||
| REF 3 | National Cancer Institute. NCI Drug Dictionary. 2009 (CdrID=456793) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.